APAlexandra Perrin

Alexandra Perrin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alexandra Perrin has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Development, Usability Testing, and Pilot Randomized Controlled Trial of WeCareToFeedDysphagia: A Web-Based Tool to Reduce Burden in Caregivers of Community-Dwelling Persons with Dementia and Oropharyngeal Dysphagia (Preprint)

    by Liron Sinvani, Michael A. Diefenbach, Alexandra Perrin, Samantha Gordon, Stefani Slotnick, Stephanie Groton, Nur-E Ferdous, Mahdia Parker, Huma Babar, Codruta Chiuzan, et al.

  • Open Access

    Development, Usability Testing, and Pilot Randomized Controlled Trial of WeCareToFeedDysphagia: A Web-Based Tool to Reduce Burden in Caregivers of Community-Dwelling Persons with Dementia and Oropharyngeal Dysphagia (Preprint)

    by Liron Sinvani, Michael A. Diefenbach, Alexandra Perrin, Samantha Gordon, Stefani Slotnick, Stephanie Groton, Nur-E Ferdous, Mahdia Parker, Huma Babar, Codruta Chiuzan, et al.

    BACKGROUND Oropharyngeal dysphagia (dysphagia) affects up to 86% of hospitalized patients with Alzheimer disease (AD) and AD-related dementias (AD/ADRD) and is a significant predictor of caregiver burden. Upon hospital discharge, caregivers face dramatic and persistent unmet dysphagia-related caregiving needs, yet no single comprehensive resource exists to address these needs. OBJECTIVE To develop (Aim 1), test the usability/acceptability (Aim 2), and conduct a pilot feasibility randomized controlled trial (RCT; Aim 3) of a web-based caregiver tool for feeding in dysphagia (WeCareToFeedDysphagia), designed to reduce burden in caregivers of community-dwelling persons with AD/ADRD and dysphagia. METHODS The study was conducted in three phases: (1) semi-structured interviews with 15 caregivers to develop website content; (2) usability/acceptability testing with 20 caregivers (all 20 completed Round 1) using the think-aloud method, discrete navigation tasks, and the System Usability Scale (SUS); and (3) a fully remote, two-arm pilot feasibility RCT (N=80) across 11 heterogeneous hospitals, randomizing caregivers to enhanced control (usual care + speech-language pathologist referral) or intervention (enhanced control + WeCareToFeedDysphagia), with assessments at baseline, 1-month, and 3-months post-hospital discharge. The primary objective of Aim 3 was to evaluate feasibility for a full-scale effectiveness RCT; clinical outcome analyses were exploratory. RESULTS Four primary qualitative themes emerged and consistent feedback was integrated: caregiver experience with dysphagia, dysphagia-related information gaps, hospital discharge deficiencies, and website content feedback. Among the 20 caregivers who completed usability testing, the average task success rate was 94% and the mean SUS score was 90.8 (SD=10.29), indicating high usability. In phase 3 (pilot feasibility RCT), we met 6 of 6 go/no-go feasibility milestones (i.e., consent rate, attrition, initial and follow-up text receipt, home page access, and tool engagement). The observed effect size (Cohen's d) for the exploratory primary clinical outcome (caregiver burden at 3 months) was -0.1 (95% CI: −0.6 to 0.4). Unadjusted, baseline-adjusted, and longitudinal analyses did not demonstrate statistically significant between-group differences in burden. A nominally significant difference was observed on the CarerQol-VAS happiness scale at 3 months (intervention 6.1 vs. control 4.9, mean difference:1.2, 95% CI: 0.1 to 2.3; P=.03); however, this finding was one of multiple exploratory comparisons without multiplicity adjustment and should be considered hypothesis-generating. CONCLUSIONS To our knowledge, WeCareToFeedDysphagia is the first stakeholder-informed, evidence-based, centralized web-based tool for caregivers of persons with AD/ADRD and dysphagia. It demonstrated high usability and acceptability. The pilot feasibility RCT demonstrated strong feasibility, meeting all pre-specified go/no-go milestones. These findings support transition to an NIH Stage IV (R33) full-scale effectiveness RCT (N=802). CLINICALTRIAL ClinicalTrials.gov NCT06557863; https://clinicaltrials.gov/study/NCT06557863

  • Open Access

    Multicomponent Behavior Change Technique Intervention for Caregivers of People With Alzheimer Disease and Related Dementias: Protocol for a Single-Arm, Personalized Behavioral Trial to Disrupt Sedentary Time

    by Danielle Miller, Sherene Lambert, Luis Jordan, Mark J Butler, Liron Sinvani, Alexandra Perrin, Ying Kuen Cheung, Karina W Davidson, Ashley M Goodwin

    Background: Sedentary behavior is associated with negative health outcomes. High levels of sedentary behavior are common among Alzheimer disease and related dementias (ADRD) caregivers already at risk of other adverse health effects, yet few interventions target sedentary behavior within this population. There is a need for trials intended to reduce time spent sedentary, which may be achievable by increasing the frequency of disruptions to sedentary time. Remotely delivered behavior change techniques (BCTs) may be effective for disrupting sedentary behavior in this population through short bursts of walking, although it is unclear how BCTs promote this behavior and potentially act via the hypothesized mechanism of behavioral automaticity. Objective: The goal of the trial is to examine whether a significant proportion of ADRD caregivers (≥50%) receiving an SMS text message–delivered BCT intervention form a habit to engage in hourly walking 4 times per day, with the broader objective of disrupting sedentary time in this population. Methods: This trial is a 12-week, decentralized, single-arm, National Institutes of Health Stage II behavioral trial. The trial will deliver a personalized, multicomponent BCT intervention to disrupt time spent sedentary by encouraging forming a habit of hourly walking among caregivers of persons with ADRD via the key mechanism of behavior change behavioral automaticity. The intervention includes 4 daily SMS text message–delivered BCT components previously used in interventions to disrupt sedentary behavior—Goal setting, Action planning, Prompts/cues, and Self-monitoring. Formation of an hourly walking habit is the primary outcome and will be defined as walking an additional 250 steps or more per hour for the same 4 consecutive hours as set up in a personalized walking plan on 7 consecutive days. Secondary outcomes include evaluating associations between habit formation and behavioral automaticity, and between longitudinal behavioral automaticity and habitual hourly walking over time. Additionally, heterogeneity of treatment effects will be evaluated. Exploratory analyses will examine potential moderating variables that may influence the intervention effect. The trial uses digital enrollment strategies, SMS text message intervention delivery, passive data collection via Fitbit (Google) devices, and online survey assessments to collect data remotely. Results: This study was funded by the National Institute on Aging in June 2024. Recruitment and data collection began in March 2025. As of August 2025, 40% (n=40) of the planned sample has been enrolled. Data collection is expected to be complete by June 2026. Data analysis and publication of results are expected by Fall and Winter 2026, respectively. Conclusions: Results will have the potential to advance knowledge about the effectiveness of BCTs to form a habit of hourly walking and may provide opportunities for future public health impact to promote physical activity in caregivers of those living with ADRD.

  • Open Access

    A Series of Personalized Melatonin Supplement Interventions for Poor Sleep: Feasibility Randomized Crossover Trial for Personalized N-of-1 Treatment

    by Mark J Butler, Thevaa Chandereng, Heejoon Ahn, Stefani Slotnick, Danielle Miller, Alexandra Perrin, Jordyn Rodillas, Ciaran P Friel, Ashley M Goodwin, Ying Kuen Cheung, et al.

    Background: Poor sleep (defined by short sleep duration or poor quality) is a common condition with potential serious health consequences. Exogenous melatonin supplements have been found to effectively improve poor sleep but have also been shown to have heterogeneity of treatment effects (HTEs) between individuals. Personalized N-of-1 trials, in which each participant is the unit of analysis, are ideal for identifying whether a treatment with high HTE is beneficial for each individual patient. Objective: This study aimed to identify the feasibility, acceptability, and effectiveness of a series of personalized N-of-1 trials of melatonin for poor sleep. Methods: This study consisted of 60 digital, personalized N-of-1 crossover trials comparing the effects of 3.0 mg and 0.5 mg of melatonin versus placebo for poor sleep with randomization to 1 of 2 orders. The trial comprised a 2-week baseline period and a 12-week intervention period. The primary outcomes were usability of the personalized trial system (measured using the System Usability Scale [SUS]) and participant satisfaction with the trial. Effectiveness outcomes included sleep duration (measured using a Fitbit activity tracker [Google]) and sleep quality (measured using the consensus sleep diary). Results: Participants rated the usability of the personalized trial as acceptable (average SUS score 76.3, SD 17.1), and 96% (55/57) of those who completed satisfaction surveys stated that they would recommend the trial to others. Importantly, indices of HTE were low for 3.0 mg and 0.5 mg doses of melatonin, indicating that the effect of these treatments on sleep duration and sleep quality did not substantially vary between participants and that averaged treatment responses are appropriate. Averaged participant sleep duration did not significantly differ between the 3.0 mg (P=.70) and 0.5 mg (P=.90) melatonin intervention periods and the baseline period. In addition, regression models did not show differences between different levels of melatonin and placebo periods for sleep duration or quality. Conclusions: Participant ratings of the usability of and satisfaction with this series of personalized N-of-1 trials of melatonin for sleep suggest these trials are both feasible and acceptable. However, our results show that melatonin supplements did not significantly improve sleep duration or sleep quality. Furthermore, the treatment effects’ lack of heterogeneity among participants suggests that future use of N-of-1 trials of melatonin for poor sleep is not needed.


  • Open Access

    Digital, Personalized Clinical Trials Among Older Adults, Lessons Learned From the COVID-19 Pandemic, and Directions for the Future: Aggregated Feasibility Data From Three Trials Among Older Adults

    by Lindsay Arader, Danielle Miller, Alexandra Perrin, Frank Vicari, Ciaran P Friel, Elizabeth A Vrany, Ashley M Goodwin, Mark Butler

    Background: The COVID-19 pandemic was extremely disruptive to clinical practice and research. Given older adults’ increased likelihood of chronic health concerns, limited resources, and greater risk for adverse outcomes of COVID-19, access to research participation during this time was critical, particularly to interventions that may impact health conditions or behaviors. Fortunately, the implementation of personalized, digital research trials during the pandemic allowed for research and intervention delivery for older adults to continue remotely, resulting in feasibility findings that can benefit researchers, practitioners, and the broader older adult population. Objective: This study discusses 3 digital, remote, and personalized intervention trials implemented during the pandemic to increase physical activity (2 trials) or to reduce back pain (1 trial). Methods: We identified measures used for all 3 trials including Fitbit activity monitor use and self-reported participant satisfaction. Participant levels of Fitbit activity monitor use and satisfaction ratings of the digital trials were compared between younger (younger than 55 years) and older adults (older than 55 years). Differences between these cohorts were analyzed using chi-square tests for categorical outcomes and 2-tailed independent-sample t tests for continuous outcomes. Results: Across the 3 trials, the majority of participants reported high satisfaction with the usability of the trials’ digital systems including SMS text message interventions and surveys (≥62% satisfied) and the use of wearable devices such as Fitbits (≥81% satisfied). In addition, the use of the Fitbit device was shown to be feasible, as older adults across all trials wore their Fitbits for the majority of the day (mean 20.3, SD 3.6 hours). Furthermore, consistent Fitbit wear was common; 100% of participants older than 55 years wore their Fitbit an average of 10 or more hours per day. These trials highlight that digital, remote intervention delivery may be successfully implemented among older adults by way of personalized trials. Across the 3 digital interventions, feasibility and acceptability were high among older adults, and comparable to younger adults. Conclusions: Given the success of the current trials amid pandemic restrictions, we argue that these trials serve as a useful framework to aid in designing personalized, digital, remote interventions in other areas of clinical care among older adults and in planning for future disruptions including new pandemics.


  • Top Cited Papers

    Thick Liquids and Clinical Outcomes in Hospitalized Patients With Alzheimer Disease and Related Dementias and Dysphagia

    by Alexander Makhnevich, Alexandra Perrin, Dristi Talukder, Yan Liu, Stephanie Izard, Codruta Chiuzan, Stefani D’aNgelo, Rebecca Affoo, Nicole Rogus-Pulia, Liron Sinvani

    Importance: Oropharyngeal dysphagia is common in hospitalized patients with Alzheimer disease and related dementias (ADRD). Although the use of thick liquids in patients with dysphagia has been shown to reduce aspiration on direct visualization, there is no clear evidence that this practice translates into improved clinical outcomes.Objectives: To determine whether a diet of thick liquids compared with thin liquids is associated with improved outcomes in hospitalized patients with ADRD and dysphagia.Design, Setting, and Participants: This cohort study included adults aged 65 years and older with ADRD who were admitted to the medicine service across 11 diverse hospitals in New York between January 1, 2017, and September 20, 2022, with clinical suspicion of dysphagia during hospitalization and survival for at least 24 hours after hospital arrival. Patients were grouped according to whether at least 75% of their hospital diet consisted of a thick liquid diet or a thin liquid diet. Propensity score matching was used to balance covariates across the 2 groups for the following covariates: demographics (eg, age, sex), baseline clinical characteristics (eg, Charlson Comorbidity Index), and acute presentation (eg, respiratory diagnosis, illness severity, delirium).Main Outcomes and Measures: Hospital outcomes included mortality (primary outcome), respiratory complications (eg, pneumonia), intubation, and hospital length of stay (LOS).Results: Of 8916 patients with ADRD and dysphagia included in the propensity score matched analysis, the mean (SD) age was 85.7 (8.0) years and 4829 were female (54.2%). A total of 4458 patients receiving a thick liquid diet were matched with 4458 patients receiving a thin liquid diet. There was no significant difference in hospital mortality between the thick liquids and thin liquids groups (hazard ratio, 0.92; 95% CI, 0.75-1.14]; P = .46). Compared with patients receiving thin liquids, patients receiving thick liquids were less likely to be intubated (odds ratio [OR], 0.66; 95% CI, 0.54-0.80), but they were more likely to have respiratory complications (OR, 1.73; 95% CI, 1.56-1.91).Conclusions and Relevance: This cohort study emphasizes the need for prospective studies that evaluate whether thick liquids are associated with improved clinical outcomes in hospitalized patients with ADRD and dysphagia.


  • Open Access

    A Series of Personalized Melatonin Supplement Interventions for Poor Sleep: Feasibility Randomized Crossover Trial for Personalized N-of-1 Treatment (Preprint)

    by Mark J. Butler, Thevaa Chandereng, Heejoon Ahn, Stefani D’angelo, Danielle Miller, Alexandra Perrin, Jordyn Rodillas, Ciaran P. Friel, Ashley M. Goodwin, Ying Kuen Cheung, et al.

    BACKGROUND Poor sleep (defined by short sleep duration or poor quality) is a common condition with potential serious health consequences. Exogeneous melatonin supplements have been found to effectively improve poor sleep but have also been shown to have heterogeneity of treatment effects (HTEs) between individuals. Personalized N-of-1 trials, in which each participant is the unit of analysis, are ideal for identifying whether a treatment with high HTE is beneficial for each individual patient. OBJECTIVE This study aimed to identify the feasibility, acceptability, and effectiveness of a series of personalized N-of-1 trials of melatonin for poor sleep. METHODS This study consisted of 60 digital, personalized N-of-1 crossover trials comparing the effects of 3.0mg and 0.5mg of melatonin versus placebo for poor sleep with randomization to 1 of 2 orders. The trial was comprised of a 2-week baseline period and a 12-week intervention period. The primary outcomes were usability of the personalized trial system (measured using the System Usability Scale [SUS]) and participant satisfaction with the trial. Effectiveness outcomes included sleep duration (measured using a Fitbit activity tracker) and sleep quality (measured using the consensus sleep diary [CSD]). RESULTS Participants rated the usability of the personalized trial as acceptable (average SUS score=76.3 [standard deviation (SD)=17.1]), and 96% (55/57) of those who completed satisfaction surveys stated that they would recommend the trial to others. Importantly, indices of HTE were low for 3.0mg and 0.5mg doses of melatonin, indicating that the effect of these treatments on sleep duration and sleep quality did not substantially vary between participants and that averaged treatment responses are appropriate. Averaged participant sleep duration did not significantly differ between the 3.0mg (P=0.7) and 0.5mg (P=0.9) melatonin intervention periods and the baseline period. Additionally, regression models did not show differences between different levels of melatonin and placebo periods for sleep duration or quality. CONCLUSIONS Participant ratings of the usability of and satisfaction with this series of personalized N-of-1 trials of melatonin for sleep suggest these trials are both feasible and acceptable. However, our results show that melatonin supplements did not significantly improve sleep duration or sleep quality. Further, the treatment effects’ lack of heterogeneity between participants suggests that future use of N-of-1 trials of melatonin for poor sleep is not needed.

  • Open Access

    Digital, Personalized Clinical Trials Among Older Adults, Lessons Learned From the COVID-19 Pandemic, and Directions for the Future: Aggregated Feasibility Data From Three Trials Among Older Adults (Preprint)

    by Lindsay Arader, Danielle Miller, Alexandra Perrin, Frank Vicari, Ciaran P Friel, Elizabeth A Vrany, Ashley M Goodwin, Mark Butler

    BACKGROUND The COVID-19 pandemic was extremely disruptive to clinical practice and research. Given older adults’ increased likelihood of chronic health concerns, limited resources, and greater risk for adverse outcomes of COVID-19, access to research participation during this time was critical, particularly to interventions that may impact health conditions or behaviors. Fortunately, the implementation of personalized, digital research trials during the pandemic allowed for research and intervention delivery for older adults to continue remotely, resulting in feasibility findings that can benefit researchers, practitioners, and the broader older adult population. OBJECTIVE This study discusses 3 digital, remote, and personalized intervention trials implemented during the pandemic to increase physical activity (2 trials) or to reduce back pain (1 trial). METHODS We identified measures used for all 3 trials including Fitbit activity monitor use and self-reported participant satisfaction. Participant levels of Fitbit activity monitor use and satisfaction ratings of the digital trials were compared between younger (younger than 55 years) and older adults (older than 55 years). Differences between these cohorts were analyzed using chi-square tests for categorical outcomes and 2-tailed independent-sample t tests for continuous outcomes. RESULTS Across the 3 trials, the majority of participants reported high satisfaction with the usability of the trials’ digital systems including SMS text message interventions and surveys (≥62% satisfied) and the use of wearable devices such as Fitbits (≥81% satisfied). In addition, the use of the Fitbit device was shown to be feasible, as older adults across all trials wore their Fitbits for the majority of the day (mean 20.3, SD 3.6 hours). Furthermore, consistent Fitbit wear was common; 100% of participants older than 55 years wore their Fitbit an average of 10 or more hours per day. These trials highlight that digital, remote intervention delivery may be successfully implemented among older adults by way of personalized trials. Across the 3 digital interventions, feasibility and acceptability were high among older adults, and comparable to younger adults. CONCLUSIONS Given the success of the current trials amid pandemic restrictions, we argue that these trials serve as a useful framework to aid in designing personalized, digital, remote interventions in other areas of clinical care among older adults and in planning for future disruptions including new pandemics. CLINICALTRIAL

  • Open Access

    A Series of Personalized Virtual Light Therapy Interventions for Fatigue: Feasibility Randomized Crossover Trial for N-of-1 Treatment

    by Mark Butler, Stefani D’aNgelo, Heejoon Ahn, Thevaa Chandereng, Danielle Miller, Alexandra Perrin, Anne-Marie N Romain, Ava Scatoni, Ciaran P Friel, Ying-Kuen Cheung, et al.

    Background: Fatigue is one of the most common symptoms treated in primary care and can lead to deficits in mental health and functioning. Light therapy can be an effective treatment for symptoms of fatigue; however, the feasibility, scalability, and individual-level heterogeneity of light therapy for fatigue are unknown.Objective: This study aimed to evaluate the feasibility, acceptability, and effectiveness of a series of personalized (N-of-1) interventions for the virtual delivery of bright light (BL) therapy and dim light (DL) therapy versus usual care (UC) treatment for fatigue in 60 participants.Methods: Participants completed satisfaction surveys comprising the System Usability Scale (SUS) and items assessing satisfaction with the components of the personalized trial. Symptoms of fatigue were measured using the Patient-Reported Outcomes Measurement Information System (PROMIS) daily, PROMIS weekly, and ecological momentary assessment (EMA) questionnaires delivered 3 times daily. Comparisons of fatigue between the BL, DL, and UC treatment periods were conducted using generalized linear mixed model analyses between participants and generalized least squares analyses within individual participants.Results: Participants rated the usability of the personalized trial as acceptable (average SUS score=78.9, SD 15.6), and 92% (49/53) of those who completed satisfaction surveys stated that they would recommend the trial to others. The levels of fatigue symptoms measured using the PROMIS daily fatigue measure were lower or improved in the BL (B=−1.63, 95% CI −2.63 to −0.63) and DL (B=−1.44, 95% CI −2.50 to −0.38) periods relative to UC. The treatment effects of BL and DL on the PROMIS daily measure varied among participants. Similar findings were demonstrated for the PROMIS weekly and EMA measures of fatigue symptoms.Conclusions: The participant scores on the SUS and satisfaction surveys suggest that personalized N-of-1 trials of light therapy for fatigue symptoms are both feasible and acceptable. Both interventions produced significant (P<.05) reductions in participant-reported PROMIS and EMA fatigue symptoms relative to UC. However, the heterogeneity of these treatment effects across participants indicated that the effect of light therapy was not uniform. This heterogeneity along with high ratings of usability and satisfaction support the use of personalized N-of-1 research designs in evaluating the effect of light therapy on fatigue for each patient. Furthermore, the results of this trial provide additional support for the use of a series of personalized N-of-1 research trials.Trial Registration: ClinicalTrials.gov NCT04707846; https://clinicaltrials.gov/ct2/show/NCT04707846


  • Open Access

    A Series of Remote Melatonin Supplement Interventions for Poor Sleep: Protocol for a Feasibility Pilot Study for a Series of Personalized (N-of-1) Trials

    by Mark Butler, Stefani D’aNgelo, Alexandra Perrin, Jordyn Rodillas, Danielle Miller, Lindsay Arader, Thevaa Chandereng, Ying Kuen Cheung, Ari Shechter, Karina W Davidson

    Background: Poor sleep, defined as short-duration or poor-quality sleep, is a frequently reported condition with many deleterious effects including poorer cognitive functioning, increased accidents, and poorer health. Melatonin has been shown to be an efficacious treatment to manage symptoms of poor sleep. However, the treatment effects of melatonin on sleep can vary greatly between participants. Personalized, or N-of-1, trial designs represent a method for identifying the best treatment for individual participants. Although using N-of-1 trials of melatonin to treat poor sleep is possible, the feasibility, acceptability, and effectiveness of N-of-1 trials using melatonin are unknown. Using the National Institutes of Health Stage Model for Behavioral Intervention Development, a stage IB (intervention refinement, modification, and adaptation and pilot testing) design appeared to be needed to address these feasibility questions. Objective: This trial series evaluates the feasibility, acceptability, and effectiveness of a series of personalized interventions for remote delivery of melatonin dose (3 and 0.5 mg) versus placebo supplements for self-reported poor sleep among 60 participants. The goal of this study is to provide valuable information about implementing remote N-of-1 randomized controlled trials to improve poor sleep. Methods: Participants will complete a 2-week baseline followed by six 2-week alternating intervention periods of 3 mg of melatonin, 0.5 mg of melatonin, and placebo. Participants will be randomly assigned to 2 intervention orders. The feasibility and acceptability of the personalized trial approach will be determined with participants’ ratings of usability and satisfaction with the remote, personalized intervention delivery system. The effectiveness of the intervention will be measured using participants’ self-reported sleep quality and duration and Fitbit tracker–measured sleep duration and efficiency. Additional measures will include ecological momentary assessment measures of fatigue, stress, pain, mood, concentration, and confidence as well as measures of participant adherence to the intervention, use of the Fitbit tracker, and survey data collection. Results: As of the submission of this protocol, recruitment for this National Institutes of Health stage IB personalized trial series is approximately 78.3% complete (47/60). We expect recruitment and data collection to be finalized by June 2023. Conclusions: Evaluating the feasibility, acceptability, and effectiveness of a series of personalized interventions of melatonin will address the longer term aim of this program of research—is integrating N-of-1 trials useful patient care? The personalized trial series results will be published in a peer-reviewed journal and will follow the CONSORT (Consolidated Standards of Reporting Trials) extension for N-of-1 trials (CENT 2015) reporting guidelines. This trial series was approved by the Northwell Health institutional review board. Trial Registration: ClinicalTrials.gov NCT05349188; https://www.clinicaltrials.gov/study/NCT05349188 International Registered Report Identifier (IRRID): DERR1-10.2196/45313